Grail Files for IPO Ahead of Launching Multi-Cancer Liquid Biopsy Screening TestAnnals of Oncology, Business, Cancer, Cancer Tissue, Clinical Data, Genetic Cancer Tests, Genome Sequencing, Initial Public Offering (IPO), Investors, Liquid Biopsy Screening Tests, Spin-Outs, U.S. Securities and Exchange Commission (SEC)U.S-based cancer testing startup Grail Inc., a spin out of genome sequencing firm Illumina, filed a preliminary prospectus for a $100 million initial public offering (IPO) with the U.S. Securities and Exchange Commission. Read more September 14, 2020/by Andrew Humphreys https://www.pharmalive.com/wp-content/uploads/2020/09/Grail-Files-for-IPO-Ahead-of-Launching-Multi-Cancer-Liquid-Biopsy-Screening-Test-BioSpace-9-14-20.jpeg 350 625 Andrew Humphreys https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png Andrew Humphreys2020-09-14 23:08:272020-09-14 23:09:48Grail Files for IPO Ahead of Launching Multi-Cancer Liquid Biopsy Screening Test